Q4 EPS Estimate for Stoke Therapeutics Increased by Analyst

Stoke Therapeutics, Inc. (NASDAQ:STOK) – Equities research analysts at Leerink Partnrs increased their Q4 2024 earnings per share estimates for shares of Stoke Therapeutics in a report released on Tuesday, October 15th. Leerink Partnrs analyst M. Goodman now anticipates that the company will earn ($0.53) per share for the quarter, up from their prior estimate of ($0.54). Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.11) per share. Leerink Partnrs also issued estimates for Stoke Therapeutics’ FY2026 earnings at ($1.80) EPS, FY2027 earnings at ($2.20) EPS and FY2028 earnings at ($1.70) EPS.

A number of other equities research analysts have also weighed in on STOK. HC Wainwright restated a “buy” rating and issued a $35.00 target price on shares of Stoke Therapeutics in a report on Wednesday, September 11th. Leerink Partners initiated coverage on Stoke Therapeutics in a report on Monday, October 14th. They set an “outperform” rating and a $18.00 price objective for the company. Needham & Company LLC restated a “buy” rating and issued a $22.00 target price on shares of Stoke Therapeutics in a report on Thursday, August 8th. Finally, Wedbush reaffirmed an “outperform” rating and set a $17.00 target price on shares of Stoke Therapeutics in a research report on Thursday, July 11th. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $20.83.

Stoke Therapeutics Trading Down 2.0 %

STOK opened at $13.00 on Friday. The company has a market cap of $677.57 million, a price-to-earnings ratio of -5.39 and a beta of 0.97. The company’s fifty day moving average price is $13.69 and its two-hundred day moving average price is $13.70. Stoke Therapeutics has a 1-year low of $3.35 and a 1-year high of $17.58.

Stoke Therapeutics (NASDAQ:STOK) last issued its earnings results on Wednesday, August 7th. The company reported ($0.46) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.11. Stoke Therapeutics had a negative return on equity of 57.89% and a negative net margin of 683.35%. The company had revenue of $4.83 million for the quarter, compared to analysts’ expectations of $3.33 million.

Insiders Place Their Bets

In other Stoke Therapeutics news, major shareholder Skorpios Trust sold 1,937,500 shares of the company’s stock in a transaction on Thursday, September 19th. The stock was sold at an average price of $14.05, for a total value of $27,221,875.00. Following the completion of the transaction, the insider now owns 8,906,181 shares in the company, valued at $125,131,843.05. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 11.30% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Nisa Investment Advisors LLC lifted its stake in Stoke Therapeutics by 53.2% in the second quarter. Nisa Investment Advisors LLC now owns 2,989 shares of the company’s stock valued at $40,000 after purchasing an additional 1,038 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its position in shares of Stoke Therapeutics by 5.5% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 31,431 shares of the company’s stock valued at $425,000 after buying an additional 1,642 shares during the last quarter. The Manufacturers Life Insurance Company grew its stake in shares of Stoke Therapeutics by 16.7% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 13,964 shares of the company’s stock worth $189,000 after acquiring an additional 1,994 shares during the period. Quest Partners LLC purchased a new stake in Stoke Therapeutics in the 2nd quarter worth about $29,000. Finally, Los Angeles Capital Management LLC raised its stake in Stoke Therapeutics by 7.2% in the 2nd quarter. Los Angeles Capital Management LLC now owns 66,765 shares of the company’s stock valued at $902,000 after acquiring an additional 4,508 shares during the period.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.